All In Biotech

Drug Trial Radar · NCT00481871

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies

Last checked: Nov 20, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

May 2007

Primary completion

May 2011

Study completion Aug 2011

Sponsor

Lead sponsor
Acrotech Biopharma Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma (HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's macroglobulinemia. This study is being done to find doses of the combination of pralatrexate and gemcitabine with vitamin B12 and folic acid that can be safely given to patients with these types of lymphoma and explore the effectiveness of the treatment.

Conditions

  • Relapsed or Refractory Lymphoproliferative Malignancies
  • Hodgkin's Lymphoma
  • Peripheral T-cell Lymphoma
  • B-cell Lymphoma
  • Waldenstrom's Macroglobulinemia

Interventions

  • Pralatrexate InjectionDrug

    Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.

  • Gemcitabine HydrochlorideDrug

    Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions. Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met. Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.

  • Vitamin B12Dietary supplement

    1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

  • Folic AcidDietary supplement

    1 mg orally Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Responses Assessed by International Workshop Criteria (IWC)Time frame: Assessed every 8 weeks (+/- 1 week) for Phase II and no less than every 3 cycles for Phase I

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of California at Los Angeles

    Los Angeles, California

  • Stanford University School of Medicine

    Stanford, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • University of Chicago Hospital

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • The Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • New York University Hospital

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Cancer Therapy & Research Center

    San Antonio, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.